2B Blackbio, dedicated to developing and marketing new solutions for personalized medicine, has obtained CE Marking for BlackLight Fungal ID Kit, intended for a fast and easy‐to‐use diagnostic test, allowing rapid identification of fungal infections.
BlackLight Fungal ID Kit allows the detection and identification of the most clinically relevant fungi and yeast species by microsequencing (Candida and Aspergillus), responsible for about 95% of all invasive fungal diseases characterized by a high mortality rate (30-40%). BlackLight Fungal ID Kit minimizes handling, being faster than traditional methods currently on the market for routine diagnostics in hospitals and intensive care units.
In recent years there has been an exponential increase in the incidence of serious fungal infections associated mainly with Candida and Aspergillus, with high morbidity and mortality. These are often associated with surgery, organ transplants, tumors and intensive care patients, and the epidemiology of these infections is changing in parallel with advances in clinical practice, transforming the risk population.
In January, the company, based in Spain, announced its completion of its second capital increase and financial support of more than 3 million Euros that will allow the company to continue with the development of personalized medicine solutions and its international expansion.
The Personalized Medicine market is projected to grow 11.56 percent annually and expected to reach US$ 148.4 Billion by 2015. Other companies making advancements in the field of personalized medicine include BioNanomatrix, Ion Channel Innovations, Axial Biotech, and Clarient.